Flow Cytometry News and Research

RSS

Flow cytometry is a technique for counting and examining microscopic particles suspended in a stream of fluid. It allows simultaneous multiparametric analysis of the physical and/or chemical characteristics of single cells flowing through an optical and/or electronic detection apparatus.

Analysis of the immune landscape in mild-to-moderate COVID-19

A new study includes an analysis of plasma cytokine levels, peripheral blood immune cell composition, and SARS-CoV-2 specific Igs in COVID-19.

15 Sep 2021

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

In a research paper recently uploaded to the medRxiv* preprint server by Capelle et al. (September 2nd, 2021), the immune response of mild and hospitalized COVID-19 patients is compared, finding that early T-cell response is a vital indicator of SARS-CoV-2 disease severity.

15 Sep 2021

Metabolic and immune markers as tools for risk stratification and monitoring in COVID-19

In a new study posted to the medRxiv* server scientists from Weil Cornell University and Stony Brook University in New York attempted to identify the metabolic and immune markers associated with severe COVID-19 disease using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. This will facilitate risk stratification, monitoring, and therapeutic interventions in COVID-19 patients.

14 Sep 2021

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

A group of researchers analyzed the B cell response to SARS-CoV-2 in unexposed individuals.

10 Sep 2021

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

Researchers study the role of low-density granulocytes in COVID-19

Information on granulocytes helps to understand mechanisms associated with covid-19 and other infectious diseases. Such information also promotes the development of better diagnostic methods and therapies.

30 Aug 2021

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.

26 Aug 2021

MSK researchers identify potential biomarker of response to checkpoint immunotherapy

In recent years, immune-based treatments for cancer have buoyed the hopes of doctors and patients alike. Drugs called immune checkpoint inhibitors have provided lifesaving benefits to a growing list of people with several types of cancer, including melanoma, lung cancer, bladder cancer, and many more.

25 Aug 2021

Persistence of Anti-PF4 levels in VITT patients four months after AstraZeneca COVID-19 vaccine

A study published on medRxiv* preprint server reported the over-time changes in the ability of the serum to activate platelets in vitro.

25 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

Biotium releases new ExoBrite EV Membrane Staining Kits

Biotium, a leading supplier and inventor of fluorescent cellular probes for life science research, announces the release of new ExoBrite™ EV Membrane Staining Kits.

17 Aug 2021

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

A new study published in the journal Nature Communications has reported two neutralizing antibodies, namely, nCoVmab1 and nCoVmab2, which are potent against SARS-CoV-2.

13 Aug 2021

New insight into impact of SARS-CoV-2 mutations on receptor binding

A recent study by Canadian researchers, currently available on the bioRxiv* preprint server, contributes to the growing body of literature on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by appraising the impact of single mutations on their overall antigenicity and binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor.

9 Aug 2021

Long COVID may be due to persistent immune disturbances

A new study discusses abnormalities in the immune response following COVID-19 in samples collected from patients who have recovered from COVID-19.

8 Aug 2021

New study examines B cell receptor repertoires in COVID-19 patients

In a paper recently uploaded to the preprint server bioRxiv* by Kim et al. (August 2, 2021), the B cell receptor repertoire of 1,060 COVID-19 patients is compared to that of an equal number of healthy volunteers in a novel manner, utilizing computational deep-learning-based protein embedding techniques, which demonstrate a resolution capable of tracking the changes in immunity in an individual over the course of infection.

5 Aug 2021

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

A study analyzes the immune responses of medical personnel, as well as immunocompromised DP and immunosuppressed KTR patients.

27 Jul 2021

Variations in human ACE2 genetics associated with coronavirus susceptibility

In a recent study, the researchers sought to understand the genetic variability in ACE2 that may contribute to inconsistent clinical outcomes of COVID-19.

25 Jul 2021

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.